- Q1 2024 Aclaris Therapeutics Inc Earnings Call TranscriptMay 07, 2024$1.3 (-4.55%)Earnings
- Aclaris Therapeutics Inc to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results Call TranscriptNov 13, 2023
- Aclaris Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Aclaris Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2023$8.89Earnings
- Aclaris Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Aclaris Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 12, 2022
- Aclaris Therapeutics Inc R&D Day (Virtual) TranscriptDec 07, 2021
- Aclaris Therapeutics Inc ATI-1777 Clinical Data Call TranscriptJun 08, 2021
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 03, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJan 19, 2021
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 17, 2020
- Aclaris Therapeutics Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- Q4 2019 Aclaris Therapeutics Inc Earnings Call TranscriptFeb 25, 2020$1.31Earnings
- Q3 2019 Aclaris Therapeutics Inc Earnings Call TranscriptNov 07, 2019$1.17Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptOct 24, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptSep 27, 2019
- Q2 2019 Aclaris Therapeutics Inc Earnings Call TranscriptAug 08, 2019$2.12Earnings
- Aclaris Therapeutics, Inc. - Special Call TranscriptJul 30, 2019
- Aclaris Therapeutics, Inc. - Special Call TranscriptJun 26, 2019
- Aclaris Therapeutics Presents 6-Month Results From Androgenetic Alopecia Study TranscriptJun 17, 2019
- Q1 2019 Aclaris Therapeutics Inc Earnings Call TranscriptMay 08, 2019$6.41Earnings
- Q4 2018 Aclaris Therapeutics Inc Earnings Call TranscriptMar 18, 2019Earnings
Q1 2023 Aclaris Therapeutics Inc Earnings Call Transcript
Good day, and thank you for standing by. Welcome to Aclaris Therapeutics First Quarter 2023 Conference Call. (Operator Instructions)
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Robert Doody, Head of Investor Relations. Please go ahead.
Thank you. I am Robert Doody, Head of Investor Relations for Aclaris. Please note that earlier today, we issued a press release highlighting our first quarter 2023 financial results and other business matters. For those of you who have not yet seen it, you will find the press release posted under the Press Releases page of the Investors section of our website, www.aclaristx.com.
In addition, we will be referring to a slide deck entitled Q1 2023 Investor Conference Call, which can be found on the Investor page of our corporate website and furnished as an exhibit to our Form 8-K that we filed with the SEC
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)